^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Papitrol (tirvalimogene teraplasmid)

i
Other names: GX-188E, GX-188, pGX27-E6E7, NOV1702
Company:
Genexine, National OncoVenture
Drug class:
Immunostimulant
Related drugs:
9ms
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid)
9ms
Enrollment change • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
over1year
Lunit to Present 16 Abstracts at the 2023 ASCO Annual Meeting (PRNewswire)
"Lunit...announced the presentation of 16 abstracts featuring its AI-biomarker platform at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago, Illinois, on June 2-6."
Clinical data • P2 data
|
Lunit SCOPE IO
|
Keytruda (pembrolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
over1year
Combination therapy • Enrollment open • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 IHC 28-8 pharmDx
|
Opdivo (nivolumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
over2years
Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
over2years
KEYNOTE-567: The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer (clinicaltrials.gov)
P1/2, N=60, Active, not recruiting, Genexine, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> Dec 2022
Enrollment closed • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid)
over2years
New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
over2years
Combination therapy • New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 IHC 28-8 pharmDx
|
Opdivo (nivolumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
over4years
The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer (clinicaltrials.gov)
P1/2, N=60, Recruiting, Genexine, Inc. | N=46 --> 60 | Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2020 --> Dec 2021
Clinical • Enrollment change • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid)
over4years
[VIRTUAL] Efficacy and safety results of pembrolizumab combined with GX-188E, a therapeutic DNA vaccine administration in patients with HPV 16- and/or 18- positive advanced cervical cancer: Phase II interim analysis results (AACR-I 2020)
Pembrolizumab combined with GX-188E demonstrated a higher response rate than pembrolizumab monotherapy in patients with cervical cancer showing great synergy regardless of PD-L1 expression. The safety profile was manageable and similar to that of pembrolizumab monotherapy. Further evaluation of anti-tumor response and antigen specific immune response is ongoing in a larger number of patients with and without PD-L1 expression.
Clinical • P2 data • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid)